Page 88 - Clinical Development News Today

/PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced...

Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript September 5, 2023 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $2.16, expectations were $-2.68. Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a […]

Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer Appointments of Fredrik and Peter complete build-out of senior team London— 6 September 2023— Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, has appointed Fredrik Erlandson as Chief Medical Officer and Peter Mulcahy as Chief People Officer. These two key additional appointments complete Purespring’s le...

BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Development as well as ROCTAVIAN and VOXZOGO New Indication Opportunities R&D Day to be Webcast...

CAMBRIDGE, Mass., Sept. 06, 2023 -- Biogen Inc. announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member...

/PRNewswire/ -- PLT Health Solutions, Inc announced the completion of a six-month clinical study on its AprèsFlex® 5-Day Joint Support ingredient in...

IRVINE, Calif.--(BUSINESS WIRE)--Sep 5, 2023--

/PRNewswire/ -- Agilisium Consulting, the pioneering leader in data analytics, cloud, and life science solutions, is pleased to announce the appointment of Dr....

- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m2,the threshold for kidney dysfunction,receiving TransCon PTH experienced eGFR improvement to above 60 mL/min/1.73m2.

The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.